Physiologic benefits of pulsatile perfusion during mechanical circulatory support for the treatment of acute and chronic heart failure in adults

Yulong Guan, Tushar Karkhanis, Shigang Wang, Alan Rider, Steven C. Koenig, Mark S. Slaughter, Aly El Banayosy, Akif Undar

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

A growing population experiencing heart failure (100 000 patients/year), combined with a shortage of donor organs (less than 2200 hearts/year), has led to increased and expanded use of mechanical circulatory support (MCS) devices. MCS devices have successfully improved clinical outcomes, which are comparable with heart transplantation and result in better 1-year survival than optimal medical management therapies. The quality of perfusion provided during MCS therapy may play an important role in patient outcomes. Despite demonstrated physiologic benefits of pulsatile perfusion, continued use or development of pulsatile MCS devices has been widely abandoned in favor of continuous flow pumps owing to the large size and adverse risks events in the former class, which pose issues of thrombogenic surfaces, percutaneous lead infection, and durability. Next-generation MCS device development should ideally implement designs that offer the benefits of rotary pump technology while providing the physiologic benefits of pulsatile end-organ perfusion.

Original languageEnglish (US)
Pages (from-to)529-536
Number of pages8
JournalArtificial Organs
Volume34
Issue number7
DOIs
StatePublished - Jan 1 2010

Fingerprint

Pulsatile Flow
Heart Failure
Equipment and Supplies
Rotary pumps
Perfusion
Play Therapy
Durability
Heart Transplantation
Therapeutics
Lead
Pumps
Tissue Donors
Technology
Survival
Infection
Population

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

Guan, Yulong ; Karkhanis, Tushar ; Wang, Shigang ; Rider, Alan ; Koenig, Steven C. ; Slaughter, Mark S. ; El Banayosy, Aly ; Undar, Akif. / Physiologic benefits of pulsatile perfusion during mechanical circulatory support for the treatment of acute and chronic heart failure in adults. In: Artificial Organs. 2010 ; Vol. 34, No. 7. pp. 529-536.
@article{7989e0317dd84bc0bdef3ce48c553e0f,
title = "Physiologic benefits of pulsatile perfusion during mechanical circulatory support for the treatment of acute and chronic heart failure in adults",
abstract = "A growing population experiencing heart failure (100 000 patients/year), combined with a shortage of donor organs (less than 2200 hearts/year), has led to increased and expanded use of mechanical circulatory support (MCS) devices. MCS devices have successfully improved clinical outcomes, which are comparable with heart transplantation and result in better 1-year survival than optimal medical management therapies. The quality of perfusion provided during MCS therapy may play an important role in patient outcomes. Despite demonstrated physiologic benefits of pulsatile perfusion, continued use or development of pulsatile MCS devices has been widely abandoned in favor of continuous flow pumps owing to the large size and adverse risks events in the former class, which pose issues of thrombogenic surfaces, percutaneous lead infection, and durability. Next-generation MCS device development should ideally implement designs that offer the benefits of rotary pump technology while providing the physiologic benefits of pulsatile end-organ perfusion.",
author = "Yulong Guan and Tushar Karkhanis and Shigang Wang and Alan Rider and Koenig, {Steven C.} and Slaughter, {Mark S.} and {El Banayosy}, Aly and Akif Undar",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1525-1594.2010.00996.x",
language = "English (US)",
volume = "34",
pages = "529--536",
journal = "Artificial Organs",
issn = "0160-564X",
publisher = "Wiley-Blackwell",
number = "7",

}

Physiologic benefits of pulsatile perfusion during mechanical circulatory support for the treatment of acute and chronic heart failure in adults. / Guan, Yulong; Karkhanis, Tushar; Wang, Shigang; Rider, Alan; Koenig, Steven C.; Slaughter, Mark S.; El Banayosy, Aly; Undar, Akif.

In: Artificial Organs, Vol. 34, No. 7, 01.01.2010, p. 529-536.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Physiologic benefits of pulsatile perfusion during mechanical circulatory support for the treatment of acute and chronic heart failure in adults

AU - Guan, Yulong

AU - Karkhanis, Tushar

AU - Wang, Shigang

AU - Rider, Alan

AU - Koenig, Steven C.

AU - Slaughter, Mark S.

AU - El Banayosy, Aly

AU - Undar, Akif

PY - 2010/1/1

Y1 - 2010/1/1

N2 - A growing population experiencing heart failure (100 000 patients/year), combined with a shortage of donor organs (less than 2200 hearts/year), has led to increased and expanded use of mechanical circulatory support (MCS) devices. MCS devices have successfully improved clinical outcomes, which are comparable with heart transplantation and result in better 1-year survival than optimal medical management therapies. The quality of perfusion provided during MCS therapy may play an important role in patient outcomes. Despite demonstrated physiologic benefits of pulsatile perfusion, continued use or development of pulsatile MCS devices has been widely abandoned in favor of continuous flow pumps owing to the large size and adverse risks events in the former class, which pose issues of thrombogenic surfaces, percutaneous lead infection, and durability. Next-generation MCS device development should ideally implement designs that offer the benefits of rotary pump technology while providing the physiologic benefits of pulsatile end-organ perfusion.

AB - A growing population experiencing heart failure (100 000 patients/year), combined with a shortage of donor organs (less than 2200 hearts/year), has led to increased and expanded use of mechanical circulatory support (MCS) devices. MCS devices have successfully improved clinical outcomes, which are comparable with heart transplantation and result in better 1-year survival than optimal medical management therapies. The quality of perfusion provided during MCS therapy may play an important role in patient outcomes. Despite demonstrated physiologic benefits of pulsatile perfusion, continued use or development of pulsatile MCS devices has been widely abandoned in favor of continuous flow pumps owing to the large size and adverse risks events in the former class, which pose issues of thrombogenic surfaces, percutaneous lead infection, and durability. Next-generation MCS device development should ideally implement designs that offer the benefits of rotary pump technology while providing the physiologic benefits of pulsatile end-organ perfusion.

UR - http://www.scopus.com/inward/record.url?scp=77954366506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954366506&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1594.2010.00996.x

DO - 10.1111/j.1525-1594.2010.00996.x

M3 - Review article

C2 - 20497164

AN - SCOPUS:77954366506

VL - 34

SP - 529

EP - 536

JO - Artificial Organs

JF - Artificial Organs

SN - 0160-564X

IS - 7

ER -